December 1, 2004
Research and Markets: Osteoporosis and HRT Market Forecast to Grow to $17.9 Billion By 2014
Research and Markets (http://www.researchandmarkets.com/reports/c10315) has announced the addition of Commercial Insight: Osteoporosis and HRT - Novel Osteoporosis Drugs Counter Generic Threat While HRT Players Regroup and Move Forward to their offering
The osteoporosis and HRT market was valued at $8.3 billion in 2003 and is forecast to grow to $17.9 billion by 2014, driven by a number of novel osteoporosis drug launches before 2009. Since the Women's Health Initiative (WHI), the HRT market has been in decline and nonhormonal osteoporosis drugs have partially realized the opportunity to increase market share and value, further boosting sector growth.
This report details epidemiology of female and male osteoporosis in the seven major markets and also provides country specific forecasts based on IMS MIDAS data of key ATC classes A11C2; G3C; G3E; G3F; H4A; H4V; M5B1; M5B2; M5B9/
An analysis of WHI impact on the osteoporosis and HRT market and portfolio management strategy in hormone therapy is also provided.
Case Studies provided in this report include:
Wyeth Hrt Portfolio Strategy - Preserving The Premarin Brand And Gambling On New Molecules
Bazedoxifene And Trimegestone
Nps Pre-Launch Strategy For Preos - Piggybacking Kineret Detailing Activity
Chugai Cornering The Japanese Market
Merck's Fosamax Launch Activity
Heavy Phase Iv Activity Among Top Three Drugs
Combination Trials With Forteo, Evista And Fosamax
Impact Of The Whi On Non-Hormonal Osteoporosis Drugs
For more information visit http://www.researchandmarkets.com/reports/c10315